Program
SNA02-48
A development code.
Its studies are mostly in Tetanus, led by Sinovac Biotech.
Furthest: phase 3, since Jun 2, 20262 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 21 open or running | phase 3since Jun 2, 2026 | Apr 15, 2025 | Mar 31, 2027phase 3 · NCT07633119 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2025First study: phase 2 study in TetanusFirst studyNCT06939777 · 255 enrolled · China
- Jun 2, 2026Phase 3 study in TetanusPhase 3 reachedNCT07633119 · 600 planned · China
Ahead
- Mar 31, 2027Primary completion: phase 3 study in TetanusNCT07633119
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633119Tetanus · China | 3 | Not yet recruiting | Mar 31, 2027 | 600 |
| NCT06939777Tetanus · China | 2 | Completed | Dec 8, 2025 | 255 |
How it is read
Names in the registry
- “SNA02-48”, 2 entries
Codes read as this program: SNA0248.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.